https://www.selleckchem.com/products/tpi-1.html
The most prevalent bleed type was traumatic musculoskeletal bleeding. Bleeding events occurred more often in the first 10weeks after starting emicizumab, but no time period was without bleeding events. The majority of patients were prescribed every-week or every-2-week dosing, but some had alternative dosing frequency. Real-world emicizumab use in our center was characterized by variations in prescribing practices and bleeding outcomes and lack of severe adverse reactions. Real-world emicizumab use in our center was characterized by varia
Like
Comment
Share
